Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126262711 | 12626271 | 1 | I | 20160801 | 20160805 | 20160805 | EXP | US-009507513-1608USA000828 | MERCK | 0.00 | M | Y | 0.00000 | 20160805 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126262711 | 12626271 | 1 | PS | JANUVIA | SITAGLIPTIN PHOSPHATE | 1 | Oral | UNK | 21995 | FILM-COATED TABLET | |||||||||
| 126262711 | 12626271 | 2 | SS | INVOKANA | CANAGLIFLOZIN | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126262711 | 12626271 | 1 | Blood glucose abnormal |
| 126262711 | 12626271 | 2 | Blood glucose abnormal |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126262711 | 12626271 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126262711 | 12626271 | Diabetes mellitus inadequate control | |
| 126262711 | 12626271 | Drug ineffective |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |